Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1977 Jun;28(3):490–495.

C3 metabolism in ulcerative colitis and Crohn's disease.

H J Hodgson, B J Potter, D P Jewell
PMCID: PMC1541002  PMID: 891024

Abstract

The metabolism of the third component of complement (C3) has been investigated in four patients with ulcerative colitis, three patients with Crohn's disease and seven control subjects, using radioiodinated C3 prepared from fresh human plasma. Both the fractional catabolic rate and synthesis rate of C3 were increased in the patients with inflammatory bowel disease, although the serum-C3 levels were normal or raised. The results suggest that complement activation may play a role in the pathogenesis of mucosal inflammation in these diseases.

Full text

PDF
490

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERSON S. A., YALOW R. S. Distribution and metabolism of I131 labeled proteins in man. Fed Proc. 1957 Jul;16(2):suppl–18. [PubMed] [Google Scholar]
  2. Baklien K., Brandtzaeg P. Letter: Immunohistochemical localization of complement in intestinal mucosa. Lancet. 1974 Nov 2;2(7888):1087–1088. doi: 10.1016/s0140-6736(74)92198-9. [DOI] [PubMed] [Google Scholar]
  3. Ballard J., Shiner M. Evidence of cytotoxicity in ulcerative colitis from immunofluorescent staining of the rectal mucosa. Lancet. 1974 May 25;1(7865):1014–1017. doi: 10.1016/s0140-6736(74)90416-4. [DOI] [PubMed] [Google Scholar]
  4. CAMPBELL R. M., CUTHBERTSON D. P., MATTHEWS C. M., MCFARLANE A. S. Behaviour of 14C- and 131I-labelled plasma proteins in the rat. Int J Appl Radiat Isot. 1956 Jul;1(1-2):66–84. doi: 10.1016/0020-708x(56)90020-5. [DOI] [PubMed] [Google Scholar]
  5. Charlesworth J. A., Williams D. G., Sherington E., Peters D. K. Metabolism of the third component of complement (C3) in normal human subjects. Clin Sci Mol Med. 1974 Feb;46(2):223–229. doi: 10.1042/cs0460223. [DOI] [PubMed] [Google Scholar]
  6. De Dombal F. T., Burton I. L., Clamp S. E., Goligher J. C. Short-term course and prognosis of Crohn's disease. Gut. 1974 Jun;15(6):435–443. doi: 10.1136/gut.15.6.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Doe W. F., Booth C. C., Brown D. L. Evidence for complement-binding immune complexes in adult coeliac disease, Crohn's disease, and ulcerative colitis. Lancet. 1973 Feb 24;1(7800):402–403. doi: 10.1016/s0140-6736(73)90254-7. [DOI] [PubMed] [Google Scholar]
  8. HJERTEN S., LEVIN O., TISELIUS A. Protein chromatography on calcium phosphate columns. Arch Biochem Biophys. 1956 Nov;65(1):132–155. doi: 10.1016/0003-9861(56)90183-7. [DOI] [PubMed] [Google Scholar]
  9. Jewell D. P., MacLennan I. C. Circulating immune complexes in inflammatory bowel disease. Clin Exp Immunol. 1973 Jun;14(2):219–226. [PMC free article] [PubMed] [Google Scholar]
  10. Lagercrantz R., Hammarström S., Perlmann P., Gustafsson B. E. Immunological studies in ulcerative colitis. 3. Incidence of antibodies to colon-antigen in ulcerative colitis and other gastro-intestinal diseases. Clin Exp Immunol. 1966 Jul;1(3):263–276. [PMC free article] [PubMed] [Google Scholar]
  11. MATTHEWS C. M. The theory of tracer experiments with 131I-labelled plasma proteins. Phys Med Biol. 1957 Jul;2(1):36–53. doi: 10.1088/0031-9155/2/1/305. [DOI] [PubMed] [Google Scholar]
  12. McFarlane A. S., Koj A. Short-term measurement of catabolic rates using iodine-labeled plasma protein. J Clin Invest. 1970 Oct;49(10):1903–1911. doi: 10.1172/JCI106409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Monteiro E., Fossey J., Shiner M., Drasar B. S., Allison A. C. Antibacterial antibodies in rectal and colonic mucosa in ulcerative colitis. Lancet. 1971 Feb 6;1(7693):249–250. doi: 10.1016/s0140-6736(71)90997-4. [DOI] [PubMed] [Google Scholar]
  14. NILSSON U. R., MUELLER-EBERHARD H. J. ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med. 1965 Aug 1;122:277–298. doi: 10.1084/jem.122.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Potter B. J., Elias E., Jones E. A. Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis. J Lab Clin Med. 1976 Sep;88(3):427–439. [PubMed] [Google Scholar]
  16. THAYER W. R., Jr, SPIRO H. M. Persistence of serum complement in sera of patients with ulcerative colitis. J Lab Clin Med. 1963 Jul;62:24–30. [PubMed] [Google Scholar]
  17. TRUELOVE S. C., WITTS L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Teisberg P., Gjone E. Humoral immune system activity in inflammatory bowel disease. Scand J Gastroenterol. 1975;10(5):545–549. [PubMed] [Google Scholar]
  19. Ward M., Eastwood M. A. Proceedings: Serum complement components C3 and C4 in inflammatory bowel disease. Gut. 1974 Oct;15(10):835–835. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES